Capacity Growth Eirgen Pharma is expanding with a new state-of-the-art manufacturing facility in 2025, boosting capacity to over 500 million units annually, which creates opportunities to outsource high-potency and specialty OSD production for growing demand.

High Potency Focus Specialization in high containment and high potency OSD manufacturing positions Eirgen as a preferred partner for companies developing challenging molecules that require strict safety and regulatory compliance across global markets.

Lifecycle Support Capabilities cover full product lifecycle from early-stage formulation development and clinical trial supply to large-scale commercial manufacturing and packaging, enabling end-to-end CDMO/CMO partnerships for pharma and veterinary clients.

Global Compliance Recent HPRA-approved expansion and emphasis on regulatory compliance across markets highlight readiness to support international launches, attractive for sponsors seeking reliable, scaled manufacturing with robust governance.

Industry Engagement Active participation in European life sciences events and a growing leadership team signal a commitment to growth, visibility, and deal-making, offering sales opportunities through partnerships and licensing discussions.